Observational studyJapanese journal of clinical oncology2025

Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer.

Tsuyoshi Hirata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.